17beta-estradiol multiple interactions ISO RGD:1601858 6480464 EGF protein inhibits the reaction [Estradiol results in decreased expression of CSGALNACT1 mRNA] CTD PMID:24758408 17beta-estradiol multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSGALNACT1 mRNA CTD PMID:32741896 17beta-estradiol decreases expression ISO RGD:1601858 6480464 Estradiol results in decreased expression of CSGALNACT1 mRNA CTD PMID:24758408 17beta-estradiol 3-benzoate multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSGALNACT1 mRNA CTD PMID:32741896 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1601858 6480464 Dihydrotestosterone results in increased expression of CSGALNACT1 mRNA CTD PMID:29581250 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of CSGALNACT1 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of CSGALNACT1 mRNA CTD PMID:33387578 3,3',5,5'-tetrabromobisphenol A decreases expression EXP 6480464 tetrabromobisphenol A results in decreased expression of CSGALNACT1 mRNA CTD PMID:28300664 4,4'-sulfonyldiphenol increases expression ISO RGD:1316918 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of CSGALNACT1 mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide increases expression ISO RGD:1316918 6480464 Fenretinide results in increased expression of CSGALNACT1 mRNA CTD PMID:28973697 acetamide increases expression EXP 6480464 acetamide results in increased expression of CSGALNACT1 mRNA CTD PMID:31881176 aflatoxin B1 increases expression ISO RGD:1601858 6480464 Aflatoxin B1 results in increased expression of CSGALNACT1 mRNA CTD PMID:21632981 aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of CSGALNACT1 mRNA CTD PMID:33354967 aflatoxin B1 decreases methylation ISO RGD:1601858 6480464 Aflatoxin B1 results in decreased methylation of CSGALNACT1 intron CTD PMID:30157460 aflatoxin B1 increases methylation ISO RGD:1601858 6480464 Aflatoxin B1 results in increased methylation of CSGALNACT1 gene CTD PMID:27153756 all-trans-retinoic acid increases expression ISO RGD:1601858 6480464 Tretinoin results in increased expression of CSGALNACT1 mRNA CTD PMID:21934132 , PMID:33167477 antirheumatic drug decreases expression ISO RGD:1601858 6480464 Antirheumatic Agents results in decreased expression of CSGALNACT1 mRNA CTD PMID:24449571 arsenous acid increases expression ISO RGD:1601858 6480464 Arsenic Trioxide results in increased expression of CSGALNACT1 mRNA CTD PMID:20458559 benzo[a]pyrene decreases expression ISO RGD:1316918 6480464 Benzo(a)pyrene results in decreased expression of CSGALNACT1 mRNA CTD PMID:21569818 benzo[a]pyrene affects methylation ISO RGD:1601858 6480464 Benzo(a)pyrene affects the methylation of CSGALNACT1 5' UTR, Benzo(a)pyrene affects the methylation of CSGALNACT1 promoter CTD PMID:27901495 benzo[a]pyrene increases methylation ISO RGD:1601858 6480464 Benzo(a)pyrene results in increased methylation of CSGALNACT1 exon CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:1316918 6480464 Benzo(a)pyrene results in increased expression of CSGALNACT1 mRNA CTD PMID:22228805 , PMID:22610609 benzo[a]pyrene decreases expression ISO RGD:1601858 6480464 Benzo(a)pyrene results in decreased expression of CSGALNACT1 mRNA CTD PMID:20106945 , PMID:21632981 benzo[a]pyrene increases expression ISO RGD:1601858 6480464 Benzo(a)pyrene results in increased expression of CSGALNACT1 mRNA CTD PMID:22316170 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of CSGALNACT1 mRNA CTD PMID:21839799 benzo[a]pyrene diol epoxide I affects expression ISO RGD:1601858 6480464 7 more ... CTD PMID:20382639 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1601858 6480464 7 more ... CTD PMID:19150397 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1601858 6480464 Diethylhexyl Phthalate results in increased expression of CSGALNACT1 mRNA CTD PMID:31163220 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of CSGALNACT1 mRNA CTD PMID:25181051 more ... bisphenol A decreases methylation ISO RGD:1601858 6480464 bisphenol A results in decreased methylation of CSGALNACT1 gene CTD PMID:31601247 bisphenol A multiple interactions ISO RGD:1601858 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of CSGALNACT1 gene CTD PMID:31601247 bisphenol A increases expression ISO RGD:1316918 6480464 bisphenol A results in increased expression of CSGALNACT1 mRNA CTD PMID:30951980 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of CSGALNACT1 gene CTD PMID:28505145 bisphenol A decreases expression ISO RGD:1601858 6480464 bisphenol A results in decreased expression of CSGALNACT1 mRNA CTD PMID:27685785 bisphenol F increases expression ISO RGD:1316918 6480464 bisphenol F results in increased expression of CSGALNACT1 mRNA CTD PMID:30951980 butanal decreases expression ISO RGD:1601858 6480464 butyraldehyde results in decreased expression of CSGALNACT1 mRNA CTD PMID:26079696 calcitriol increases expression ISO RGD:1601858 6480464 Calcitriol results in increased expression of CSGALNACT1 mRNA CTD PMID:21592394 calcitriol multiple interactions ISO RGD:1601858 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of CSGALNACT1 mRNA CTD PMID:21592394 carbamazepine affects expression ISO RGD:1601858 6480464 Carbamazepine affects the expression of CSGALNACT1 mRNA CTD PMID:25979313 carmustine affects response to substance ISO RGD:1601858 6480464 CSGALNACT1 mRNA affects the susceptibility to Carmustine CTD PMID:16365179 cisplatin multiple interactions ISO RGD:1601858 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of CSGALNACT1 mRNA CTD PMID:27392435 cobalt dichloride decreases expression ISO RGD:1601858 6480464 cobaltous chloride results in decreased expression of CSGALNACT1 mRNA CTD PMID:19376846 copper(II) sulfate decreases expression ISO RGD:1601858 6480464 Copper Sulfate results in decreased expression of CSGALNACT1 mRNA CTD PMID:19549813 cyclosporin A decreases expression ISO RGD:1601858 6480464 Cyclosporine results in decreased expression of CSGALNACT1 mRNA CTD PMID:27989131 cylindrospermopsin increases expression ISO RGD:1601858 6480464 cylindrospermopsin results in increased expression of CSGALNACT1 mRNA CTD PMID:24921660 diarsenic trioxide increases expression ISO RGD:1601858 6480464 Arsenic Trioxide results in increased expression of CSGALNACT1 mRNA CTD PMID:20458559 diethylstilbestrol increases expression EXP 6480464 Diethylstilbestrol results in increased expression of CSGALNACT1 mRNA CTD PMID:17005392 dioxygen increases expression ISO RGD:1601858 6480464 Oxygen deficiency results in increased expression of CSGALNACT1 mRNA CTD PMID:26516004 diuron decreases expression EXP 6480464 Diuron results in decreased expression of CSGALNACT1 mRNA CTD PMID:25152437 dorsomorphin multiple interactions ISO RGD:1601858 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of CSGALNACT1 mRNA CTD PMID:29391264 enzalutamide decreases expression ISO RGD:1601858 6480464 enzalutamide results in decreased expression of CSGALNACT1 mRNA CTD PMID:29581250 ethanol affects expression ISO RGD:1316918 6480464 Ethanol affects the expression of CSGALNACT1 mRNA CTD PMID:30319688 etoposide affects response to substance ISO RGD:1601858 6480464 CSGALNACT1 protein affects the susceptibility to Etoposide CTD PMID:16217747 fulvestrant multiple interactions ISO RGD:1601858 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of CSGALNACT1 gene CTD PMID:31601247 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of CSGALNACT1 mRNA CTD PMID:33387578 hydrogen peroxide affects expression ISO RGD:1601858 6480464 Hydrogen Peroxide affects the expression of CSGALNACT1 mRNA CTD PMID:20044591 hydroquinone increases expression ISO RGD:1601858 6480464 hydroquinone results in increased expression of CSGALNACT1 mRNA CTD PMID:31256213 lead(0) affects expression ISO RGD:1601858 6480464 Lead affects the expression of CSGALNACT1 mRNA CTD PMID:28903495 lead(2+) affects expression ISO RGD:1601858 6480464 Lead affects the expression of CSGALNACT1 mRNA CTD PMID:28903495 lipopolysaccharide multiple interactions ISO RGD:1601858 6480464 [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CSGALNACT1 mRNA CTD PMID:35811015 MeIQx decreases expression ISO RGD:1601858 6480464 2-amino-3 more ... CTD PMID:20816883 niclosamide multiple interactions ISO RGD:1601858 6480464 Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CSGALNACT1 mRNA] CTD PMID:27542212 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of CSGALNACT1 mRNA CTD PMID:25729387 ozone multiple interactions ISO RGD:1316918 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of CSGALNACT1 mRNA CTD PMID:34911549 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of CSGALNACT1 mRNA CTD PMID:33387578 phenylmercury acetate increases expression ISO RGD:1601858 6480464 Phenylmercuric Acetate results in increased expression of CSGALNACT1 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1601858 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA CTD PMID:27188386 pyrvinium multiple interactions ISO RGD:1601858 6480464 pyrvinium inhibits the reaction [PIK3CA protein modified form results in decreased expression of CSGALNACT1 mRNA] CTD PMID:27542212 quercetin increases expression ISO RGD:1601858 6480464 Quercetin results in increased expression of CSGALNACT1 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1601858 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of CSGALNACT1 mRNA CTD PMID:23557933 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1601858 6480464 [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CSGALNACT1 mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1601858 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1601858 6480464 Silicon Dioxide analog results in increased expression of CSGALNACT1 mRNA CTD PMID:23806026 silicon dioxide decreases expression ISO RGD:1601858 6480464 Silicon Dioxide results in decreased expression of CSGALNACT1 mRNA CTD PMID:34973136 sodium arsenite increases expression ISO RGD:1601858 6480464 sodium arsenite results in increased expression of CSGALNACT1 mRNA CTD PMID:29301061 Soman decreases expression EXP 6480464 Soman results in decreased expression of CSGALNACT1 mRNA CTD PMID:19281266 succimer multiple interactions ISO RGD:1601858 6480464 [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of CSGALNACT1 mRNA CTD PMID:26378955 temozolomide affects response to substance ISO RGD:1601858 6480464 CSGALNACT1 mRNA affects the susceptibility to temozolomide CTD PMID:16365179 testosterone multiple interactions ISO RGD:1601858 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of CSGALNACT1 mRNA CTD PMID:21592394 testosterone multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSGALNACT1 mRNA CTD PMID:32741896 testosterone increases expression ISO RGD:1601858 6480464 Testosterone results in increased expression of CSGALNACT1 mRNA CTD PMID:21592394 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of CSGALNACT1 mRNA CTD PMID:25729387 trimellitic anhydride decreases expression ISO RGD:1316918 6480464 trimellitic anhydride results in decreased expression of CSGALNACT1 mRNA CTD PMID:19042947 valproic acid decreases methylation ISO RGD:1601858 6480464 Valproic Acid results in decreased methylation of CSGALNACT1 gene CTD PMID:29154799 valproic acid multiple interactions ISO RGD:1601858 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1601858 6480464 Valproic Acid results in increased expression of CSGALNACT1 mRNA CTD PMID:23179753 more ... zidovudine multiple interactions ISO RGD:1601858 6480464 [Zidovudine co-treated with IFNA1 protein] results in increased expression of CSGALNACT1 mRNA CTD PMID:20370541
